NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 -- Regenerative medicine company Mesoblast Limited today reported 2014 financial results and unveiled its strategy to prioritize and bring to market clinically differentiated products based on its proprietary Mesenchymal Precursor or Stem Cell technologies.
http://ift.tt/1qJBPjD
http://ift.tt/1qJBPjD
No comments:
Post a Comment